The CDMO Curia, fresh off an expansion a year ago, is scaling up manufacturing for a candidate from an Australian biotech.

Incannex Healthcare, a biotech centered on producing cannabinoid-based medicines and psychedelic therapies, is using Curia Global to further develop and manufacture a GMP-grade inhaled drug product for the treatment of concussion and traumatic brain injury originally developed by the biotech.

Evaxion Biotech, a Danish startup that uses AI to develop personalized immuno-oncology therapies, is shaking up its C-suite.

Lars Staal Wegner has decided to exit as the company’s CEO, Evaxion announced Tuesday, but will remain in an advisory role to the new CEO and board of directors. Per Norlén, who has over 20 years in the industry, will take over as the new CEO in six months.

Previously, Norlén was the CEO of Targinta and CMO of Xintela.

The latest biotech to sound the alarm comes from a David Hung startup, and it comes a little over a month after receiving a series of FDA holds.

Nuvation Bio announced Monday it would discontinue development on one of its early-stage clinical programs after regulators halted a handful of studies in late June. On top of this, Nuvation plans to lay off 30 employees, representing about 35% of its workforce, according to an SEC filing.

GSK announced this morning in a London Stock Exchange filing that Laurie Glimcher, president and CEO of the Dana-Farber Cancer Institute, has advised the company of her intention to retire from its board of directors on Oct. 13.

The company did not disclose why Glimcher has decided to move on now after more than five years as a non-executive director, but Glimcher’s appointment heralded a much bigger interest in oncology at GSK, and she’s moving on now as GSK’s R&D chief Hal Barron also hits the exit.

Pennsylvania biotech Trevena put out word Thursday morning that it slashed 25% of its full-time staff and terminated a sales force agreement with Syneos, on top of a data readout it touted as positive.

The biotech’s only approved product, marketed as Olinvyk, was OK’ed back in 2020 for moderate to severe acute pain. The opioid was originally spurned by the FDA back in 2018 after efficacy data was mixed compared to morphine at key doses and the agency wanted more safety data. Two years later, it got approved for use in a hospital setting, also getting a black box warning about addiction, abuse, respiratory depression and more.

Bob Duggan is getting help in the chief executive spot. The billionaire’s title looks a little different as of Tuesday, when Summit Therapeutics COO Maky Zanganeh was promoted to co-CEO and president.

Both sit on the board of directors of the California biotech, which is in the midst of raising $100 million in a public offering to boost the company’s coffers ahead of a likely new Phase III trial for a C. difficile asset that has been through multiple hurdles in recent memory. Duggan became CEO in April 2020, and Zanganeh joined in November of that year. The two previously worked together at Duggan’s Pharmacyclics, with the executive partners architecting a $21 billion exit to AbbVie in 2015.